This feature highlights changes in clinical research organizations’ personnel.
Executive shakeup continues at Gilead, where chief scientific officer and R&D head John McHutchison will leave the company next month. Hutchison, a nine-year veteran of the company, stepped into his current position a little more than a year ago. Gilead did not specify a reason for his departure and has not named a successor. Also leaving next month is chief patient officer Gregg Alton, who will serve in an advisory capacity until the end of the year.
MODAG has announced the appointment of Torsten Matthias as chief executive officer and Armin Giese as chief scientific officer. Matthias is the owner, CEO and CSO of worldwide operating group Aesku.Group. Giese was formerly the acting head of department at the Center for Neuropathology and Prion Research at Ludwig Maximilian University of Munich.
Elizabeth Garner has been named chief medical officer at Switzerland-based ObsEva SA. Garner most recently served as CMO and head of clinical development at Agile Therapeutics.
Dirk Brockstedt has been promoted to chief scientific officer and David Wustrow to senior vice president for drug discovery and preclinical development at RAPT Therapeutics. Brockstedt was previously the senior vice president of biology at RAPT. Wustrow was most recently vice president of discovery at FLX Bio.
CTD Holdings has named Michael Lisjak as global head of regulatory affairs and senior vice president for business development. Lisjak most recently served as head of global regulatory affairs for established products and global health at Sanofi.
Michael Cammarata has been appointed chief executive officer at Neptune Wellness Solutions Inc. Camarata is co-founder and previous chief executive officer of Schmidt’s Naturals, now a division of Unilever. He is also the founder of Random Occurrence.
Laura M. Edgerly-Pflug has been named senior vice president of technical operations at Lyra Therapeutics. Edgerly-Pflug was most recently vice president of technical operations at Adgero Biopharmaceuticals Holdings.
Progenics Pharmaceuticals has announced the appointment of Huw Jones as vice president, commercial. Jones was previously vice president of marketing and sales at Advanced Accelerator Applications.
Sunesis Pharmaceuticals has announced two key promotions. Judy Fox has been named chief scientific officer and executive vice president for research & development; Parvinder Hyare has been appointed senior vice president, commercial. Fox was previously chief scientific officer and senior vice president; Par was previously vice president of global oncology operations.
Health Enterprise Partners has announced the promotion of Elizabeth Colonna to vice president. Jessie Laurash has been named senior associate. Colonna was promoted from the position of senior associate with the company. Laurash most recently served as director of operations for MediQuire.
Anika Therapeutics has named James Loerop to the newly created position of executive vice president of business development and strategic planning. Loerop most recently served as chief corporate development officer at Lupin Pharmaceuticals.
Noel Donnelly has been appointed chief financial officer at EIP Pharma. Donnelly was most recently vice president of R&D business operations at Shire.
Tai Wong has been named vice president of oncology biology at Skyhawk Therapeutics. Wong was most recently vice president of biology at Peloton Therapeutics.
Todd Peters has been named vice president and chief medical officer at Sheppard Pratt Health System. Peters joined Sheppard Pratt in 2018 and served as its medical director of child and adolescent services and chief medical information officer.